LEU · Centrus Energy Corp. — research history

Score of 35/100 falls below the 45-point threshold. The dossier shows zero insider buying, a steep valuation premium (48x Fwd P/E, 75x EV/EBITDA), and active anti-signal gates for dilution and customer concentration. While the Oklo LOI and DOE contracts provide a catalyst, the lack of smart-money conviction and high execution/capex risk justify a skip.

Score of 35/100 falls below the 45-point threshold. The dossier shows zero insider buying, a steep valuation premium (48x Fwd P/E, 75x EV/EBITDA), and active anti-signal gates for dilution and customer concentration. While the Oklo LOI and DOE contracts provide a catalyst, the lack of smart-money conviction and high execution/capex risk justify a skip.

Centrus is the only U.S.-licensed HALEU enrichment company with active DOE contracts worth up to ~$317M funded (Phase 1, Phase 2, Option 1a through June 2026) plus three IDIQ awards ($2B combined ceiling) for LEU production, HALEU production, and HALEU deconversion. Two fresh material catalysts emerged in the last 7 days: a non-binding LOI with Oklo (June 18, 2026) to supply enough domestic HALEU to power up to five Aurora reactors starting 2029; and execution of a $900M capped construction contract (April 16, 2026) with Geiger Brothers for the Piketon expansion through January 2031. However, the stock is richly valued at forward P/E ~48x / EV/EBITDA ~75x relative to sector peers in a commodity market; no CEO/CFO open-market buys exist in the trailing window; and Q2 guidance appears to have disappointed investors who fixated on year-over-year EPS compression (stock down 21.5% since last earnings despite raising full-year revenue guidance). The OTM call whale blocks are consistent with speculative interest around the Oklo news but do not signal institutional conviction.

anti_signals: Wide bid-ask spreads (12-18%) on most strikes reduce net premium capture — limit orders required, Stock -58% from 52w high: elevated assignment risk if uranium sentiment reverses sharply, Uranium spot price volatility could spike IV further but also creates tail risk on the downside

Centrus Energy is a $3.6B-market-cap uranium fuel supplier and the only licensed HALEU producer in the Western world, backed by historic federal DOE funding ($900M+ award). The stock has collapsed from its 52w high of $436 to current ~$182 (-58%), trading 27% below its 200DMA at $248.78 — a deep technical discount that creates an attractive entry for premium collection on a name analysts target at $278 (52% upside). Earnings are NOT in any near-term expiry window: Q2 print is August 4, 2026, so June 18 (19 DTE) and July 17 (48 DTE) both clear cleanly. IV is extremely elevated: ATM 30-day implied vol runs ~76-81%, well above the anti-signal floor of sub-40 IV rank. The uranium nuclear fuel secular thesis remains intact with AI-driven data center power demand supporting nuclear renaissance. The primary structural concern is LEU's relatively wide bid-ask spreads (12-16% on most strikes) which reduces net premium capture; position sizing and limit-order discipline are mandatory.

Material anti-signal gates (customer concentration >50% to DOE, convertible overhang >10% of float) combined with rich valuation (46x Fwd PE, 85x EV/EBITDA) and bearish options positioning invalidate the setup. No smart-money support or technical momentum exists to justify a thesis.

Centrus Energy is the only U.S. company actively enriching HALEU (5-20% assay) under DOE contract, uniquely positioned in U.S. nuclear fuel supply chain with $3.8B backlog extending to 2040 and a January 2026 selection for a ~$900M commercial HALEU task order from DOE. However the stock has collapsed roughly 60% from its October 2025 peak (~$464 intraday) to $183, driven by three consecutive EPS misses (Q3/Q4 2025 both missed by ~50%, though Q1 2026 beat dramatically at +289% vs. consensus), elevated capex for Oak Ridge centrifuge manufacturing and Piketon expansion, and geopolitical uncertainty around Russian uranium trade policy. The balance sheet is strong ($1.9B cash vs $1.2B long-term debt) but near-term earnings are volatile given the company's contractor nature — revenues swing with DOE reimbursement timing. No open-market insider purchases were found in 90-day window; CFO sold shares in May 2026 (surrender for taxes on RSUs, not directional). Options flow shows heavy put bias (P/C ratio 1.78) and a new $130P with V/OI=9.2 — speculative bearish positioning but typical for high-volatility micro-cap. The thesis is long-term promising given nuclear renaissance tailwinds (AI power demand, advanced reactors, domestic security policy), but the stock is too early-cycle and uncertain to warrant an asymmetric long at current valuation (46x forward P/E, 85x EV/EBITDA) with negative operating margins on expanding capex.

Score of 18/100 reflects zero insider buying, bearish options flow, and weak technicals, compounded by active anti-signal gates for customer concentration and convertible dilution. While the DOE backlog provides a long-term catalyst, the extreme valuation (P/E 50x, EV/EBITDA 98x) and lack of near-term asymmetric upside justify a skip.

Centrus is the only US-owned uranium enrichment company and sole domestic producer of HALEU, with $3.8B in backlog extending to 2040. The most recent 8-K (April 2026) disclosed a Geiger Brothers construction contract for Piketon expansion ($900M cap). Q1 FY2026 results just reported: adjusted EPS of $1.05 crushed the $0.27 estimate (+217% surprise), with $76.7M revenue (+4.9% YoY). The January 2025 DOE award of a $900M enrichment task order is a major catalyst. However, the stock is richly valued at forward P/E of ~51x and EV/EBITDA of ~98x, has shed 57% from its October 2024 high ($464), sits below both MAs (50dma & 200dma), and options flow shows bearish bias with put/call ratio of 1.25. No open-market insider purchases in the past 90 days — all recent Form 4s are RSU vestings/tax withholding events, not directional buys by executives.